Dacogen is marketed in >30 countries for treatment of myelodysplastic syndromes. ASTX receives royalties from its marketing partner, Eisai. In 2011, received approx. $60M in royalties.
Dacogen is currently being assessed for an indication in elderly AML. Phase 3 trial (reported at ASCO) demonstrated an improved survival for a Dacogen group vs. control without any significant increase in morbidity. FDA PDUFA on 3/6/2012. EMA decision expected in Q2 2012.
Company was profitable in 2009 & 2010 and expects to be profitable in 2011.
128M in cash, no debt, cash per share = $1.35.
52 week high – $3.32, low – $1.51
Ave. vol ~300K